Can hypothyroid physiology raise homocysteine levels?

Hypothyroidism, characterized by elevated thyroid-stimulating hormone (TSH) and low free triiodothyronine (FT3), has a profound physiological impact on cardiovascular and metabolic health by directly elevating systemic homocysteine levels.

Hepatic and renal clearance mechanisms

• Hepatic enzyme downregulation: Thyroid hormone deficiency impairs the two primary pathways of hepatic homocysteine metabolism. It downregulates methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MTR), which are critical for folate- and B12-dependent remethylation. Concurrently, it downregulates cystathionine $\beta$-synthase (CBS), compromising the transsulfuration pathway.
• Impaired renal clearance: Hypothyroid physiology reduces cardiac output and renal blood flow, which decreases the glomerular filtration rate (GFR) and creatinine clearance. Because the kidneys are highly responsible for clearing homocysteine, this reduced filtration capacity directly limits systemic excretion.

Systemic accumulation and therapeutic response

• Hyperhomocysteinemia: The synergistic effect of impaired hepatic metabolic disposal (both remethylation and transsulfuration) and decreased renal GFR leads directly to the systemic accumulation of homocysteine.
• Clinical reversibility: The causal nature of this relationship is demonstrated by the therapeutic effects of thyroid hormone replacement therapy (such as levothyroxine), which restores GFR, normalizes hepatic enzyme activities, and successfully reduces plasma homocysteine levels.

Bottom line

• Hypothyroid physiology directly causes hyperhomocysteinemia by simultaneously downregulating key hepatic metabolic enzymes (MTHFR, MTR, and CBS) and reducing renal GFR, a dual impairment that is fully reversible with thyroid hormone replacement therapy.